Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Costs of illness and care in Parkinson's disease
T2 - an evaluation in six countries
AU - von Campenhausen, Sonja
AU - Winter, Yaroslav
AU - Rodrigues e Silva, Antonio
AU - Sampaio, Christina
AU - Ruzicka, Evzen
AU - Barone, Paolo
AU - Poewe, Werner
AU - Guekht, Alla
AU - Mateus, Ceu
AU - Pfeiffer, Karl-P.
AU - Berger, Karin
AU - Skoupa, Jana
AU - Bötzel, Kai
AU - Geiger-Gritsch, Sabine
AU - Siebert, Uwe
AU - Balzer-Geldsetzer, Monika
AU - Oertel, Wolfgang H.
AU - Dodel, Richard
AU - Reese, Jens P.
PY - 2011/2
Y1 - 2011/2
N2 - We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in six countries. Economic data were collected over a 6-month period and presented from the societal perspective. The total mean costs per patient ranged from EUR 2620 to EUR 9820. Direct costs totalled about 60% to 70% and indirect costs about 30% to 40% of total costs. The proportions of costs components of PD vary notably; variations were due to differences in country-specific health system characteristics, macro economic conditions, as well as frequencies of resource use and price differences. However, inpatient care, long-term care and medication were identified as the major expenditures in the investigated countries.
AB - We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in six countries. Economic data were collected over a 6-month period and presented from the societal perspective. The total mean costs per patient ranged from EUR 2620 to EUR 9820. Direct costs totalled about 60% to 70% and indirect costs about 30% to 40% of total costs. The proportions of costs components of PD vary notably; variations were due to differences in country-specific health system characteristics, macro economic conditions, as well as frequencies of resource use and price differences. However, inpatient care, long-term care and medication were identified as the major expenditures in the investigated countries.
KW - Ambulatory Care
KW - Antiparkinson Agents
KW - Cost of Illness
KW - Europe
KW - Female
KW - Health Care Costs
KW - Hospitalization
KW - Humans
KW - Long-Term Care
KW - Male
KW - Parkinson Disease
KW - Questionnaires
U2 - 10.1016/j.euroneuro.2010.08.002
DO - 10.1016/j.euroneuro.2010.08.002
M3 - Journal article
C2 - 20888737
VL - 21
SP - 180
EP - 191
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology
SN - 0924-977X
IS - 2
ER -